Teva Launches ProAir Dry Powder Digital Inhaler
Teva’s First Generic Of Merck Sharpe & Dohme Is For Asthma & COPD Patients
After getting FDA approval in 2018, Teva finally launches its ProAir Digihaler. The company will be making its complete ‘Digihaler’ portfolio available in the US by prescription later this year.
You may also be interested in...
Teva has completed its portfolio of digital inhalers by launching a further two products, AirDuo Digihaler (fluticasone propionate/salmeterol) and ArmonAir Digihaler (fluticasone propionate), in the US. The pair join the firm’s previously launched ProAir Digihaler (albuterol sulfate).
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.
Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.